1. Home
  2. AGX vs HRMY Comparison

AGX vs HRMY Comparison

Compare AGX & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGX
  • HRMY
  • Stock Information
  • Founded
  • AGX 1961
  • HRMY 2017
  • Country
  • AGX United States
  • HRMY United States
  • Employees
  • AGX N/A
  • HRMY N/A
  • Industry
  • AGX Engineering & Construction
  • HRMY Biotechnology: Pharmaceutical Preparations
  • Sector
  • AGX Consumer Discretionary
  • HRMY Health Care
  • Exchange
  • AGX Nasdaq
  • HRMY Nasdaq
  • Market Cap
  • AGX 2.1B
  • HRMY 2.0B
  • IPO Year
  • AGX N/A
  • HRMY 2020
  • Fundamental
  • Price
  • AGX $211.09
  • HRMY $32.16
  • Analyst Decision
  • AGX Buy
  • HRMY Strong Buy
  • Analyst Count
  • AGX 2
  • HRMY 9
  • Target Price
  • AGX $193.00
  • HRMY $54.22
  • AVG Volume (30 Days)
  • AGX 532.2K
  • HRMY 609.1K
  • Earning Date
  • AGX 06-04-2025
  • HRMY 08-05-2025
  • Dividend Yield
  • AGX 0.71%
  • HRMY N/A
  • EPS Growth
  • AGX 154.06
  • HRMY 13.13
  • EPS
  • AGX 7.14
  • HRMY 2.62
  • Revenue
  • AGX $910,157,000.00
  • HRMY $744,852,000.00
  • Revenue This Year
  • AGX $10.87
  • HRMY $20.10
  • Revenue Next Year
  • AGX $18.35
  • HRMY $18.01
  • P/E Ratio
  • AGX $29.57
  • HRMY $12.27
  • Revenue Growth
  • AGX 45.08
  • HRMY 20.62
  • 52 Week Low
  • AGX $63.53
  • HRMY $26.47
  • 52 Week High
  • AGX $246.60
  • HRMY $41.61
  • Technical
  • Relative Strength Index (RSI)
  • AGX 52.09
  • HRMY 43.25
  • Support Level
  • AGX $200.00
  • HRMY $31.70
  • Resistance Level
  • AGX $223.50
  • HRMY $33.69
  • Average True Range (ATR)
  • AGX 9.67
  • HRMY 0.89
  • MACD
  • AGX -2.44
  • HRMY -0.10
  • Stochastic Oscillator
  • AGX 49.44
  • HRMY 37.30

About AGX Argan Inc.

Argan Inc is a United States-based construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC, and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Telecom Services, out of which Power Services derives the majority of revenue.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: